Darren Gitelman


Director of Cognitive Disorders, Advocate Medical Group (Ill.); Neurosciences Medical Research Director and Senior Medical Director, Advocate Memory Center, Advocate Health Care

Dr. Darren Gitelman studied medicine at Washington University in St. Louis, Mo. He completed an internal medicine residency at the Columbia-Presbyterian Medical Center in New York, N.Y., followed by a fellowship in brain imaging at the New York State Psychiatric Institute. He was then a neurology resident and chief resident at the Massachusetts General Hospital in Boston, Mass. Dr. Gitelman joined the Neurology faculty at Northwestern University, Chicago, Ill., in 1994. In 2014 he joined Advocate Health as the senior medical director of the Advocate Memory Center. He is a Clinical Professor of Medicine at the Rosalind Franklin University of Medicine and Science, North Chicago, Ill., and Adjunct Associate Professor of Neurology at the Feinberg School of Medicine, Northwestern University. His current research is focused on clinical drug trials and enhancing cognitive testing in older adults.

Dr. Gitelman has engaged in consulting/advisory activities with AbbVie, Biogen, Eisai Inc., Genentech/Roche, Lilly, and Novo Nordisk. He has engaged in clinical trial investigator activities with Biogen, Cassava, Eisai Inc., and Lilly.

Read more

This Speaker's Sessions

Wednesday Oct. 18
1:30–2:15 PM
Watch Replay
Now Live!

Meeting Patient Demand for Alzheimer's Treatment

The treatment of Alzheimer’s continues to improve. As new therapies are approved by the FDA, doctors have more options for their patients, leading to better and more patient-centered care. Ideally, a patient who has a concern about their cognition will see their primary care physician, have the confidence to raise the concern, be screened for potential impairment, and if appropriate be referred to a physician with the skill, experience, and infrastructure to consider this patient for a new Alzheimer’s therapy. Key Question: What steps are leading clinicians and health systems taking to ensure that each Alzheimer’s patient who qualifies gets the right drug and in time to make a difference?

View SessionWatch Replay